Edy Ippolito

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2026

ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: June 25, 2026

Predicting 2-Year Overall Survival in NSCLC from CT Scans Using 2D CNNs and Soft Attention.

Journal: Studies in health technology and informatics

Published: May 23, 2026

Exploratory PET/CT Radiomics for Predicting Early Progression in Locally Advanced Pancreatic Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: March 30, 2026

Hidden patterns, different outcomes: un-supervised machine-learning clustering in oligometastatic gynecologic cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 11, 2026

Axillary management in patients with cN + breast cancer undergoing neoadjuvant chemotherapy: pattern of practice in Italy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 31, 2025

Handling missing modalities in multimodal survival prediction for non-small cell lung cancer.

Journal: NPJ digital medicine

Published: December 31, 2025

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 23, 2025

Virtual Treatment for radiotherapy: Multimodal generative prediction of longitudinal NSCLC tumor progression.

Journal: Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society

Published: December 15, 2025

Biochemical recurrence after radical prostatectomy: Where do we stand to?

Journal: Prostate cancer and prostatic diseases

Published: December 12, 2025

The Prone-Position Whole Breast Irradiation Paradox: Where Do We Stand? A Comprehensive Review.

Journal: Journal of clinical medicine

Published: November 13, 2025

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Journal: The oncologist

Published: June 13, 2025

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.

ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.

Predicting 2-Year Overall Survival in NSCLC from CT Scans Using 2D CNNs and Soft Attention.

Predicting 2-Year Overall Survival in NSCLC from CT Scans Using 2D CNNs and Soft Attention.

Exploratory PET/CT Radiomics for Predicting Early Progression in Locally Advanced Pancreatic Cancer.

Exploratory PET/CT Radiomics for Predicting Early Progression in Locally Advanced Pancreatic Cancer.

Hidden patterns, different outcomes: un-supervised machine-learning clustering in oligometastatic gynecologic cancer.

Hidden patterns, different outcomes: un-supervised machine-learning clustering in oligometastatic gynecologic cancer.

Axillary management in patients with cN + breast cancer undergoing neoadjuvant chemotherapy: pattern of practice in Italy.

Axillary management in patients with cN + breast cancer undergoing neoadjuvant chemotherapy: pattern of practice in Italy.

Handling missing modalities in multimodal survival prediction for non-small cell lung cancer.

Handling missing modalities in multimodal survival prediction for non-small cell lung cancer.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Virtual Treatment for radiotherapy: Multimodal generative prediction of longitudinal NSCLC tumor progression.

Virtual Treatment for radiotherapy: Multimodal generative prediction of longitudinal NSCLC tumor progression.

Biochemical recurrence after radical prostatectomy: Where do we stand to?

Biochemical recurrence after radical prostatectomy: Where do we stand to?

The Prone-Position Whole Breast Irradiation Paradox: Where Do We Stand? A Comprehensive Review.

The Prone-Position Whole Breast Irradiation Paradox: Where Do We Stand? A Comprehensive Review.

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.